Monoclonal antibody · Antagonist of Interleukin-6 receptor alpha (IL6R) · developed by Sanofi Synthelabo
Sarilumab is an interleukin-6 receptor antagonist that binds both soluble and membrane-bound IL-6 receptors and inhibits IL-6-mediated signaling. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 27, 2026). Read the full label for the exact wording, limitations and safety information.
Any Advanced Solid Tumors
Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →